DIRS.INFO The most relevant business & tech news

Losses in megacap stocks such as Microsoft Corp (MSFT.O) and Amazon.com Inc (AMZN.O) weighed on the tech-heavy Nasdaq, while gains in industrial stocks such as Caterpillar Inc (CAT.N) boosted the Dow. Hopes that the Fed will soon end its aggressive monetary policy tightening helped the S&P 500 stabilize so far in April after the collapse of two U.S. mid-sized lenders sparked a selloff last month. Analysts expect first-quarter profits at S&P 500 companies to fall 5.2% year-on-year, a stark reversal from the 1.4% annual growth expected at the beginning of the year, according to Refinitiv data. Seven of the 11 major S&P sectors rose, with gains in industrial (.SPLRCI) and material (.SPLRCM) shares offsetting losses in technology (.SPLRCT) stocks. The S&P index recorded three new 52-week highs and no new low, while the Nasdaq recorded 32 new highs and 30 new lows.

☆ Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027
▼ + stars: | 2023-04-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Moderna on Tuesday said it expects to see between $8 billion and $15 billion in sales from its Covid, RSV, flu and other respiratory vaccines in 2027. The biotech company said it sees a corresponding operating profit in the range of $4 billion to $9 billion. Those respiratory product estimates are supported by additional research investments of $6 billion to $8 billion "over the next few years," Moderna added. Moderna said earlier this year it expects $5 billion in mRNA Covid vaccine sales in 2023, a steep drop from the $18 billion the shot raked in last year. The Cambridge, Massachusetts-based company's Covid vaccine remains its only commercially available product.

☆ Moderna says there are not enough cases to declare early success for its mRNA flu vaccine
▼ + stars: | 2023-04-11 | by ( Meg Tirrell | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna says there are not enough cases to declare early success for its mRNA flu vaccineCNBC's Meg Tirrell reports on news from Moderna that it will delay results from its flu vaccine trials.

☆ Stocks making the biggest moves premarket: Moderna, CarMax, Whirlpool and more
▼ + stars: | 2023-04-11 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

CarMax — Shares of the vehicle retailer soared 7% on the back of better-than-expected quarterly earnings. Upstart — Upstart fell about 2% after JPMorgan initiated coverage of the lending stock with an underweight rating, citing a worsening environment for loans. Whirlpool — Shares gained more than 2% after Goldman Sachs upgraded Whirlpool to buy from neutral. LendingClub — The lending platform gained 4.8% after JPMorgan initiated coverage of the stock as overweight. Array Technologies — Shares of the solar technology company gained 2% after Wolfe Research initiated coverage of Array with an outperform rating.

☆ Deutsche Bank sees more than a 30% rally for this specialty biotech stock
▼ + stars: | 2023-04-10 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Deutsche Bank is more bullish on Catalent after the New Jersey-based company expanded its manufacturing partnership with Moderna . Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. CTLT YTD mountain Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share. Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. Stock Chart Icon Stock chart icon Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share.

☆ Pfizer CEO signs letter in support of FDA after federal judge suspends approval of abortion pill
▼ + stars: | 2023-04-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Pfizer 's CEO signed on to an industry letter in support of the Food and Drug Administration's authority to regulate drugs after a federal judge in Texas suspended the agency's approval of the abortion pill mifepristone. Albert Bourla was among the more than 200 pharmaceutical company executives who signed the letter after U.S. Judge Matthew Kacsmaryk's controversial ruling on Friday. Kacsmaryk sided with an anti-abortion group, arguing that the FDA rushed its approval process and violated federal standards. Kacsmaryk's decision conflicts with a ruling by a federal judge in Washington state. The dueling orders by two federal judges create a complicated legal standoff that could potentially escalate to the Supreme Court.

☆ Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
▼ + stars: | 2023-04-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna hopes to offer a new set of life-saving vaccines targeting cancer, heart disease and other conditions by 2030, a spokesperson for the company told CNBC on Monday. "It can be applied to all sorts of disease areas; we are in cancer, infectious disease, cardiovascular disease, autoimmune diseases, rare disease." Burton's remarks also come ahead of Moderna's Vaccine Day on Tuesday. He highlighted Moderna's personalized cancer vaccine, a highly anticipated mRNA shot being developed to target different tumor types. In February, the Food and Drug Administration granted Breakthrough Therapy Designation to Moderna's personalized cancer vaccine in combination with Merck's immunotherapy drug Keytruda for patients with a deadly form of skin cancer called melanoma.

☆ RSV cases in US show signs of return to pre-pandemic seasonality - CDC
▼ + stars: | 2023-04-06 | by ( ) www.reuters.com time to read: +2 min

April 6 (Reuters) - Respiratory syncytial virus (RSV) circulation is showing signs of return to pre-pandemic seasonality in the U.S. after two years of irregular onsets and peaks, the Centers for Disease Control and Prevention (CDC) said on Thursday. Typically, cases of RSV virus that can cause severe illness or death in the very young and old rose in October before waning in April. The varying timing could be challenging for drugmakers racing to get their RSV vaccines to the market. In both pre-pandemic and pandemic periods, RSV cases began to surge earlier in Florida and the Southeast and later in regions further north and west, the researchers said. "Policy makers should consider RSV seasonality when making recommendations about the timing of studies and administration of new immunization and other RSV prevention products," the report said.

☆ These S&P 500 stocks crushed it in the first quarter. Here's where analysts see them going
▼ + stars: | 2023-04-02 | by ( Fred Imbert | ) www.cnbc.com time to read: +4 min

The S & P 500 just wrapped up a wild first quarter with surprisingly strong results. The tech and communication services sectors powered the S & P 500 higher, rising more than 20% each. Here are the 10 best S & P 500 stocks for the first quarter, and where analysts see them going based on the implied upside (or downside) to their average price targets. Nvidia led the way higher among S & P 500 stocks, surging 90.1%. As for Catalent, analysts see the stock rallying 24.5% after surging 46% in the first quarter.

☆ J&J backs out of RSV vaccine race with rivals Pfizer and GSK
▼ + stars: | 2023-03-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Johnson & Johnson on Wednesday said it's ducking out of the RSV vaccine race, weeks after competitors Pfizer and GSK inched closer to launching the world's first shot against the deadly virus. J&J will stop working on its investigational RSV adult vaccine program and discontinue a pivotal phase three trial testing the shot, the company announced in a press release. Since then, the race to create the world's first RSV vaccine has garnered more attention than ever. A phase two trial on the company's RSV shot found it provided 80% protection against severe RSV infections. Drugmaker Moderna also has its own potential RSV shot, which performed well in clinical trials.

☆ China approves its first mRNA Covid-19 vaccine
▼ + stars: | 2023-03-23 | by ( Juliana Liu | ) edition.cnn.com time to read: +1 min

Hong Kong CNN —China has approved its first Covid-19 vaccine based on mRNA technology, months after the country lifted strict pandemic measures. The vaccine targets the Omicron variant and was tested in China with over 5,500 people, it added. “This is a positive step because there is strong scientific evidence that mRNA vaccines do much better than non-MRA vaccines,” Jin Dong-yan, a professor in molecular virology at the University of Hong Kong, told CNN. Until now, China has approved only inactivated vaccines made by Sinovac Biotech and Sinopharm Group, two Beijing-based drugmakers. The inactivated vaccines have been found to elicit lower levels of antibody response compared to ones using the newer messenger RNA technology.

☆ Moderna to Price Its Covid-19 Vaccine at $130 a Dose
▼ + stars: | 2023-03-22 | by ( Peter Loftus | ) www.wsj.com time to read: 1 min

The list price of Moderna’s Covid-19 vaccine is much higher than what the U.S. government has been paying. Moderna Inc. will price its Covid-19 vaccine at about $130 per dose when it shifts to commercial distribution of the shots later this year, much higher than what the federal government has paid. The plans could add to criticism of the company from lawmakers who are scheduled to explore the cost of the shots at a hearing Wednesday.

☆ Bernie Sanders Holds a Moderna Show Trial
▼ + stars: | 2023-03-22 | by ( The Editorial Board | ) www.wsj.com time to read: 1 min

No good treatment goes unpunished for pharmaceutical companies these days, and Bernie Sanders will offer another example on Wednesday when he holds a political show trial of Moderna CEO Stéphane Bancel . His offense? Cooperating with the government to produce life-saving Covid vaccines. The subject of the Vermont Senator’s hearing is Moderna’s plan to quadruple the price of its Covid vaccine to $110 to $130 per dose when U.S. government purchases stop. Pfizer has said it will charge a similar price after vaccines move to the commercial market, which is expected later this year.

☆ Moderna CEO Stephane Bancel defends fivefold price hike of Covid vaccine during Senate grilling
▼ + stars: | 2023-03-22 | by ( Spencer Kimball | ) www.cnbc.com time to read: +4 min

Moderna plans to raise the list price of its vaccine 400% to $130 when the shots are sold on the private market as early as this fall. Moderna CEO Stephane Bancel on Wednesday defended the company's plans to hike the price of its Covid shots fivefold, deflecting pressure at a Senate hearing to abandon the increase while taking barbs over his compensation. Chairman Bernie Sanders, I-Vt., questions Stephane Bancel, CEO of Moderna, during the Senate Health, Education, Labor and Pensions Committee hearing titled Taxpayers Paid Billions For It: So Why Would Moderna Consider Quadrupling the Price of the COVID Vaccine? He told the committee that the Covid vaccine market is changing substantially as the U.S. government stops buying and distributing the shots for the entire country. The Covid vaccine remains Moderna's only product on the market at the moment.

☆ Watch live: Moderna CEO Stephane Bancel testifies before Senate on Covid vaccine price hike
▼ + stars: | 2023-03-22 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

Moderna's CEO, Stephane Bancel, is testifying Wednesday before the Senate health committee on pricing of the company's Covid-19 vaccine. The Boston biotech company plans to charge $130 per dose once the vaccination program moves to the private market as early as this fall. Sen. Bernie Sanders, I-Vt., chair of the health committee, slammed Moderna in a letter to Bancel in January, calling the price hike "outrageous." Learn more and register today: http://bit.ly/3DUNbRoAfter Sanders sent the letter, Moderna said it will create an assistance program to keep the vaccine free for people who are uninsured or underinsured. People who have Medicare, Medicaid or private insurance should still receive the shot at no cost, but Sanders said the price increase "will cost taxpayers billions of dollars."

[1/3] CEO of Moderna Stephane Bancel looks up at the session "State of the Pandemic" during the World Economic Forum (WEF) in Davos, Switzerland, January 18, 2023. Moderna (MRNA.O) CEO Stephane Bancel was called to testify after the company flagged plans to raise the vaccine's price to as much as $130 per dose, drawing the ire of Democratic U.S. Senator Bernie Sanders, who chairs the influential Committee on Health, Education, Labor and Pensions (HELP). The government in May plans to end the COVID public health emergency, putting much of the vaccine purchasing in the hands of the private sector. Moderna in February forecast $5 billion in COVID vaccine sales this year, far less than the $18.4 billion windfall in 2022, due to decreasing demand for the shots.

☆ Moderna plans 400% increase in price of Covid vaccine
▼ + stars: | 2023-03-22 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna plans 400% increase in price of Covid vaccinePublic Citizen Access to Medicines Director Peter Maybarduk and Northwestern healthcare economist Craig Garthwaite joins CNBC’s Brian Sullivan and ‘Last Call’ to discuss the debate over Moderna’s decision to raise the price of its Covid vaccine.

☆ Sen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearing
▼ + stars: | 2023-03-22 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailSen. Bernie Sanders grills Moderna CEO over Covid vaccine prices during hearingCNBC's Meg Tirrell reports on the Senate hearing on drug prices, which featured an exchange between Sen. Bernie Sanders and Moderna CEO Stéphane Bancel.

☆ China OKs its first mRNA vaccine, from drugmaker CSPC
▼ + stars: | 2023-03-22 | by ( ) www.reuters.com time to read: +2 min

BEIJING, March 22 (Reuters) - China's CSPC Pharmaceutical Group Limited (1093.HK) said on Wednesday its messenger RNA (mRNA) COVID-19 vaccine had received emergency use authorisation from Chinese health authorities, making it the country's first domestically developed mRNA shot. China has declined to use mRNA vaccines from abroad and vaccines available in China are widely considered less effective than the Moderna (MRNA.O) and Pfizer (PFE.N)-BioNTech (22UAy.DE) mRNA shots. The company said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants and its booster dose showed good neutralization effect against Omicron subvariants BA.5, BF.7, BQ.1.1., XBB.1.5 and CH.1.1. The firm got emergency approval to conduct clinical trials of the mRNA shot in April last year, around the same time as CanSino, another China-based company that is testing an mRNA Omicron booster shot. Shares in the company rose as much as 7.7% after the result and the announcement of the mRNA approval.

☆ U.S. FDA to soon decide on second round of Omicron-tailored boosters - WSJ
▼ + stars: | 2023-03-21 | by ( ) www.reuters.com time to read: +2 min

The agency continues to closely monitor the emerging data in the United States and globally, and that data will dictate any decision on additional updated boosters, the FDA said in a statement. The Centers for Disease Control and Prevention would have to recommend the shots after the FDA authorizes the second Omicron-tailored boosters from Pfizer-BioNTech (PFE.N)/(22UAy.DE) and Moderna (MRNA.O) for them to become widely available. Updated boosters have helped prevent symptomatic infections against the new XBB-related subvariants, according to data released by the CDC in January. The FDA authorized the so-called bivalent COVID boosters in August that target the BA.4 and BA.5 Omicron subvariants, along with the original strain of the coronavirus. Rollout of the updated boosters in the United States started the following month.

☆ Moderna expects to price its COVID vaccine at about $130 in the US
▼ + stars: | 2023-03-21 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

REUTERS/Hannah BeierMarch 20 (Reuters) - Moderna Inc (MRNA.O) expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday. Hoge said the government's Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine. Sanders, chair of the Senate’s powerful Health, Education, Labor and Pensions Committee, has said Moderna should not raise the price of its vaccine because of the government funding it received. He plans to question Moderna Chief Executive Stephane Bancel on the price increase at the hearing on Wednesday. Moderna in February forecast significantly declining 2023 COVID-19 vaccine sales, which reached $18.4 billion in 2022.

☆ Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies
▼ + stars: | 2023-03-20 | by ( Jennifer Rigby | Thomson Reuters | Jen Reports On Health Issues Affecting People Around The World | ) www.reuters.com time to read: +5 min

There has also been a push among companies to develop a bird flu vaccine for poultry, a market potentially far larger than that for humans. Many countries' pandemic plans say flu shots should go first to the most vulnerable while supply is limited. The agreements include six of the largest seasonal flu manufacturers, such as GSK, Sanofi and CSL Seqirus, the WHO said. NEW APPROACHESIn a pandemic, vaccine manufacturers would shift production of seasonal flu vaccines and instead make shots tailored to the new outbreak when needed. The results will be closely watched, as the data on Moderna’s seasonal flu candidate was mixed.

☆ FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults
▼ + stars: | 2023-03-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

More than 12 million courses of Paxlovid have been delivered to pharmacies across the U.S., according to federal data. The FDA staff reviewed Pfizer's mid-to-late stage clinical trials of Paxlovid. In one trial called EPIC-HR, Paxlovid showed an 86% reduction in the risk of hospitalization or death in high-risk adults who hadn't received a Covid vaccine. Paxlovid has been plagued by reports of "rebound" Covid infections, where patients see their Covid symptoms or a positive test return after finishing a five-day course of the oral drug. That was also regardless of patients' risk of severe disease, or whether Covid's omicron variant or an earlier strain was dominant, according to the staff.

☆ CNBC Daily Open: The bank rout continues. The Fed might still raise rates anyway
▼ + stars: | 2023-03-14 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Bank of America tumbled 5.81% and Charles Schwab sank 11.57% even as the Schwab sought to reassure fears, saying it has "access to significant liquidity." Despite the turmoil in the banks, markets and analysts expect the Fed to go through with rate hikes. Subscribe here to get this report sent directly to your inbox each morning before markets open.

☆ CNBC Daily Open: Banks got hammered by SVB's collapse. But the Fed might still raise rates
▼ + stars: | 2023-03-14 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

The exterior of a First Republic Bank branch is seen on Barclay Street on March 13, 2023 in New York City. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. The biggest losers: First Republic Bank plunged 61.83%, Western Alliance Bancorp plummeted 57.06% and KeyCorp sank 27.33%. Despite the turmoil in the banks, markets and analysts expect the Fed to go through with rate hikes. Subscribe here to get this report sent directly to your inbox each morning before markets open.

Search resuls for: "modernă"

25 mentions found